Tim Lautenschlaeger

1.8k total citations
79 papers, 1.3k citations indexed

About

Tim Lautenschlaeger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tim Lautenschlaeger has authored 79 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Tim Lautenschlaeger's work include Lung Cancer Diagnosis and Treatment (17 papers), Glioma Diagnosis and Treatment (16 papers) and Brain Metastases and Treatment (14 papers). Tim Lautenschlaeger is often cited by papers focused on Lung Cancer Diagnosis and Treatment (17 papers), Glioma Diagnosis and Treatment (16 papers) and Brain Metastases and Treatment (14 papers). Tim Lautenschlaeger collaborates with scholars based in United States, China and Germany. Tim Lautenschlaeger's co-authors include Arnab Chakravarti, Arnab Chakravarti, Wei Meng, Sarah B. Goldberg, Veronica Chiang, Norman Yeh, Kimberly L. Johung, Neil Desai, James B. Yu and Albert Attia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Tim Lautenschlaeger

75 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Lautenschlaeger United States	17	544	529	451	415	271	79	1.3k
Douglas P. Calvin United States	7	315 0.6×	548 1.0×	433 1.0×	396 1.0×	108 0.4×	12	1.1k
Xianxin Qiu China	16	242 0.4×	329 0.6×	240 0.5×	190 0.5×	155 0.6×	46	790
Kevin S. Choe United States	15	271 0.5×	352 0.7×	143 0.3×	314 0.8×	186 0.7×	31	1.0k
Sana Yokoi Japan	21	378 0.7×	870 1.6×	297 0.7×	498 1.2×	143 0.5×	43	1.4k
Ya-Yu Tsai United States	17	555 1.0×	216 0.4×	125 0.3×	411 1.0×	357 1.3×	72	1.0k
Pavel Šlampa Czechia	15	340 0.6×	200 0.4×	197 0.4×	184 0.4×	403 1.5×	92	916
Tomáš Kazda Czechia	16	388 0.7×	166 0.3×	189 0.4×	222 0.5×	434 1.6×	101	1000
Valérie Panet-Raymond Canada	16	414 0.8×	306 0.6×	220 0.5×	306 0.7×	474 1.7×	50	1.4k
Anna Niwińska Poland	18	690 1.3×	259 0.5×	244 0.5×	737 1.8×	308 1.1×	71	1.2k
Brian Thiessen Canada	16	295 0.5×	412 0.8×	244 0.5×	220 0.5×	687 2.5×	32	1.2k

Countries citing papers authored by Tim Lautenschlaeger

Since Specialization

Citations

This map shows the geographic impact of Tim Lautenschlaeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Lautenschlaeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Lautenschlaeger more than expected).

Fields of papers citing papers by Tim Lautenschlaeger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Lautenschlaeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Lautenschlaeger. The network helps show where Tim Lautenschlaeger may publish in the future.

Co-authorship network of co-authors of Tim Lautenschlaeger

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Lautenschlaeger. A scholar is included among the top collaborators of Tim Lautenschlaeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Lautenschlaeger. Tim Lautenschlaeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weisman, Michael, Greg Andrew Durm, Misty Dawn Shields, et al.. (2024). Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 121(3). 720–727. 4 indexed citations

McClelland, Shearwood, Tim Lautenschlaeger, Albert Miller, et al.. (2023). Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): One-Year Safety and Efficacy Outcomes from a Multicenter Phase I Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S172–S172. 2 indexed citations

Mohammadi, Homan, Heather Burney, Yong Zang, et al.. (2022). Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition. Journal of Neuro-Oncology. 158(3). 481–488. 13 indexed citations

Zhang, Hong, Weili Wang, Wenhu Pi, et al.. (2021). Genetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer. Frontiers in Oncology. 11. 599719–599719. 5 indexed citations

Patel, Roshal R., Ethan B. Ludmir, Joseph A. Miccio, et al.. (2020). Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. Practical Radiation Oncology. 10(6). 423–433. 7 indexed citations

McClelland, Shearwood, Tim Lautenschlaeger, Yong Zang, et al.. (2020). Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol. Reports of Practical Oncology & Radiotherapy. 25(4). 500–506. 8 indexed citations

Arbab, Mona, et al.. (2020). Early‐stage lung adenocarcinoma treated with stereotactic body radiation therapy using a combined deep inspiration breath hold and free breathing technique: case report and literature review. 4(4). 125–128. 1 indexed citations

Elbanna, May, Kevin Shiue, Donna M. Edwards, et al.. (2020). Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy. Clinical Lung Cancer. 22(3). e342–e359. 2 indexed citations

McClelland, Shearwood, Namita Agrawal, May Elbanna, et al.. (2020). Baseline Karnofsky performance status is independently predictive of death within 30 days of intracranial radiation therapy completion for metastatic disease. Reports of Practical Oncology & Radiotherapy. 25(4). 698–700. 7 indexed citations

10.

McClelland, Shearwood, Gregory A. Durm, Thomas J. Birdas, P. Musto, & Tim Lautenschlaeger. (2019). First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy. Reports of Practical Oncology & Radiotherapy. 24(6). 507–510. 1 indexed citations

11.

Juratli, Tareq A., Sebastian Stasik, Amir Zolal, et al.. (2018). TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study. Clinical Cancer Research. 24(21). 5282–5291. 72 indexed citations

12.

Shiue, Kevin, et al.. (2018). Superior vena cava syndrome in a patient with locally advanced lung cancer with good response to definitive chemoradiation: a case report. PMC. 1 indexed citations

13.

Shiue, Kevin, et al.. (2018). Predictors of Nodal And Metastatic Failure in Early Stage Non-Small Cell Lung Cancer after Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 102(3). e676–e676. 1 indexed citations

14.

Mohammadi, Homan, Kevin Shiue, Tareq A. Juratli, et al.. (2017). Multi-institutional Series Evaluating the Rate of Pseudoprogression in Isocitrate Dehydrogenase 1 Mutated Glioblastomas. International Journal of Radiation Oncology*Biology*Physics. 99(2). E94–E95. 1 indexed citations

15.

Palanichamy, Kamalakannan, Krishnan Thirumoorthy, Suman Kanji, et al.. (2016). Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. Clinical Cancer Research. 22(14). 3513–3523. 48 indexed citations

16.

Lautenschlaeger, Tim, Oliver Oehlke, Tareq A. Juratli, et al.. (2014). A 6-gene signature for outcome prediction of grade II/III glioma.. Journal of Clinical Oncology. 32(15_suppl). 2002–2002. 1 indexed citations

17.

Meng, Wei, Zhenqing Ye, Ri Cui, et al.. (2013). MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research. 19(19). 5423–5433. 93 indexed citations

18.

Meng, Wei, Joseph P. McElroy, Stefano Volinia, et al.. (2013). Comparison of MicroRNA Deep Sequencing of Matched Formalin-Fixed Paraffin-Embedded and Fresh Frozen Cancer Tissues. PLoS ONE. 8(5). e64393–e64393. 65 indexed citations

19.

Noda, Shin‐ei, Tim Lautenschlaeger, Areej El‐Jawahri, et al.. (2009). Technological Advances in Radiation Oncology for Central Nervous System Tumors. Seminars in Radiation Oncology. 19(3). 179–186. 11 indexed citations

20.

Noda, Shin‐ei, et al.. (2009). Molecular Advances of Brain Tumors in Radiation Oncology. Seminars in Radiation Oncology. 19(3). 171–178. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact